ErVimmune - Reflections on the financing of innovative European biotechnology companies Despite the existence of numerous public support schemes, innovative biotechnology companies without clinical data (yet)particularly in oncologystill struggle to secure the private funding necessary for their development in Europe.
ERV
ErVimmune
Company · France · EU Transparency Register 488647147874-39
1
position filed
in the 326 files tracked
1
legislative file
of 326 tracked
1
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track ErVimmune in PolicySpeak: request access →
Work at ErVimmune? so we know who speaks for it.
Their record over time
ErVimmune filed 1 position on 11 Jun 2025, across 1 of the 326 legislative files tracked here, attaching a full position paper 1 time.
What they argued
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Is this your organization?
Everything on this page comes from ErVimmune’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.